Showing 93 news articles about Changing treatment

Filters Content type: Editors' picks Topic: Changing treatment

A change of HIV treatment may be necessary because of side-effects, the development of drug resistance, treatment not being fully effective or because of interactions between HIV drugs and other medications.

Changing treatment

Switching HIV Regimen to Biktarvy Is Safe and Effective for the Long Term

Editor's pick
POZ
19 October 2020
HIV treatment for children & young people

Children with perinatal HIV respond well to the switch to second-line treatment

Editor's pick
Avert
18 April 2020
Treatment outcomes & life expectancy

Only half of those on HIV treatment are virally suppressed in Ghana

Editor's pick
Avert
12 February 2020
Changing treatment

Caveat emptor: Seven things every patient should know about switching from efavirenz to dolutegravir

Editor's pick
Spotlight
25 November 2019
Treatment simplification strategies

Jitters Over New Two-Drug HIV Regimens

Editor's pick
Medscape (requires free registration)
12 November 2019
Changing treatment

FDA Expands Indications for Pifeltro and Delstrigo for HIV

Editor's pick
Medscape (requires free registration)
23 September 2019
Cardiovascular disease

Switching Back to Older Tenofovir Improves Lipid Levels

Editor's pick
POZ
12 September 2019
Changing treatment

‘Alarming’ rates of second-line HIV treatment failure in sub-Saharan Africa

Editor's pick
Avert
22 August 2019
Kidney problems

Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most?

Editor's pick
NATAP
10 August 2019
Changing treatment

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Editor's pick
i-Base
2 August 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
Changing treatment

Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

Editor's pick
Medscape (free registration required)
7 July 2019
New & experimental HIV treatments

1 Year After Approval: How Does D/C/F/TAF Measure Up?

Editor's pick
Contagion Live
1 July 2019
Treatment simplification strategies

ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

Editor's pick
ViiV press release
5 April 2019
Treatment simplification strategies

Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Editor's pick
Infectious Disease Advisor
15 February 2019
Changing treatment

FDA To Consider Pifeltro, Delstrigo as HIV Switch-On Therapies

Editor's pick
MD Magazine
23 January 2019
Treatment simplification strategies

Dolutegravir Monotherapy for HIV No Longer Recommended

Editor's pick
Contagion Live
9 January 2019
Treatment simplification strategies

Dual HIV Regimen Equaled Triple Even After Treatment Failure

Editor's pick
MD Magazine
26 November 2018
Changing treatment

Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

Editor's pick
Merck press release
5 October 2018
Changing treatment

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Editor's pick
Janssen press release
5 October 2018
Treatment simplification strategies

What you need to know about HIV two-drug regimens

Editor's pick
BETA blog
28 August 2018
Side effects

Meta-analysis of dolutegravir in naive, experienced and switch studies

Editor's pick
HIV i-Base
30 April 2018
Changing treatment

HIV Regimen Switch May Contribute to Weight Gain

Editor's pick
Monthly Prescribing Reference
9 October 2017